HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
RXRX
Recursion Pharmaceuticals, Inc.
There isn't enough reported data to score RXRX yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
RXRX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
RXRX's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
RXRX PE Valuation
RXRX has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
RXRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect RXRX's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
RXRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.86 | +$0.97 |
| Q2 2026 | -$1.00 | +$0.81 |
| Q1 2026 | -$1.16 | +$0.64 |
| Q4 2025 | -$1.44 | +$0.25 |
| Q3 2025 | -$1.83 | -$0.27 |
| Q2 2025 | -$1.81 | -$0.16 |
| Q1 2025 | -$1.80 | -$0.17 |
| Q4 2024 | -$1.69 | -$0.11 |
RXRX is still losing money, but far less than before: $0.86 per share over the past year, against $2.07 at its worst in late 2021.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over RXRX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over RXRX on profitability, with a higher operating margin.
RXRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $18.6M | +258% |
| Q2 2026 | $7.7M | -60% |
| Q1 2026 | $6.5M | -56% |
| Q4 2025 | $35.5M | +682% |
| Q3 2025 | $5.2M | -80% |
| Q2 2025 | $19.2M | +33% |
| Q1 2025 | $14.7M | +6.9% |
| Q4 2024 | $4.5M | -58% |
RXRX's revenue is growing: $19M last quarter, up 258% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -664% | +2664 points |
| Q2 2026 | -1760% | -843 points |
| Q1 2026 | -1986% | -688 points |
| Q4 2025 | -305% | +3738 points |
| Q3 2025 | -3328% | -2951 points |
| Q2 2025 | -917% | -219 points |
| Q1 2025 | -1298% | -599 points |
| Q4 2024 | -4042% | -3134 points |
RXRX's operating margin was −664% last quarter, up 2664 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over RXRX on cash generation, producing positive trailing cash flow while its opponent burns cash.
RXRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$77.8M | +$39.8M |
| Q2 2026 | -$106M | -$26.4M |
| Q1 2026 | -$81.4M | +$52.4M |
| Q4 2025 | -$47.3M | +$69.4M |
| Q3 2025 | -$117.6M | -$53.8M |
| Q2 2025 | -$79.6M | +$3.8M |
| Q1 2025 | -$133.8M | -$24.8M |
| Q4 2024 | -$116.7M | -$40.6M |
RXRX has burned cash in almost every quarter: −$312M over the past year, against −$448M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over RXRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
RXRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2% | +10.5M shares |
| 1 year | +21% | +96M shares |
| 3 years | +170% | +342M shares |
| 5 years | +2257% | +520M shares |
| Available history | +223% | +375M shares |
RXRX has 543M diluted shares, up 21% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
RXRX Net Leverage
RXRX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
RXRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.7 | Neutral |
| Stochastic | 31.6 | Neutral |
RXRX's weekly RSI is 47 (neutral) and its Stochastic is 32 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
RXRX PE vs Healthcare Sector
RXRX has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
RXRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.78 | 12% below |
| 20 week MA | $3.52 | 5.4% below |
| 50 week MA | $3.62 | 8% below |
| 100 week MA | $4.69 | 29% below |
| 200 week MA | $6.45 | 48% below |
RXRX is in a downtrend: it's below all five of its weekly moving averages, and 48% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
RXRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.3 | $16.8 | -46% |
| 2022 | $16.8 | $7.51 | -55% |
| 2023 | $7.51 | $9.86 | +31% |
| 2024 | $9.86 | $7.39 | -25% |
| 2025 | $7.39 | $4.25 | -42% |
| 2026 YTD | $4.25 | $3.33 | -22% |
RXRX has the edge over HIMS on returns for 2026, with the stronger performance.